BioSpace Movers & Shakers

ViroCell Biologics – David Enloe was appointed to the board of directors of ViroCell and Martin Pule was appointed to the company’s Scientific Advisory Board. Enloe is currently President and CEO of Recro Pharma. He was President and CEO of Ajinomoto Bio-Pharma Services and prior to that, he was the Head of Lonza’s Viral Therapeutics Business Unit. Pule is a Clinical Senior Lecturer in the Department of Hematology at University College London’s Cancer Institute and Honorary Consultant in Hematology at University College Hospital. Pule is cited as the second most prolific inventor of CAR T cells and the most prolific inventor in 2019 and 2020 respectively, by the European Patent Office.

In the NewsFlorence BuchananViroCell Board of Directors, Scientific Advisory Board, David Enloe, Lonza, University College London, gene therapy, cell therapy, CGT, viral vectors, European Patent Office, University College Hospital, Recro Pharma, BioSpace